This study is testing a drug called elritercept to see if it can help improve anemia (low red blood cell count) in adults with myelofibrosis (a bone marrow disorder) who are already taking ruxolitinib. You would receive either elritercept or a placebo (an inactive substance that looks like the study drug) through injections. Researchers want to know if elritercept helps you become independent from red blood cell transfusions for at least 12 weeks. They will also look at how elritercept affects tiredness, other myelofibrosis symptoms, physical activity, bone marrow, and the spleen, and if it's safe. The study aims to enroll 324 participants, aged 18 and older, who have been diagnosed with myelofibrosis.

Study design

This study is comparing elritercept to a placebo in 324 participants. It is a double-blinded study, meaning neither you nor your doctors will know if you are receiving elritercept or the placebo.

What's involved

You would receive study treatment for at least 9 months (36 weeks). The trial record does not specify the number of visits or procedures.

Compensation

Not stated in the trial record.

Follow-up

The primary goal is measured during a 36-week treatment period. The trial record does not specify follow-up after this period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.